| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 463 | 2022 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 445 | 2022 |
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ... New England Journal of Medicine 387 (24), 2220-2231, 2022 | 417 | 2022 |
| A multiprotein supercomplex controlling oncogenic signalling in lymphoma JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ... Nature 560 (7718), 387-391, 2018 | 407 | 2018 |
| CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021 | 332 | 2021 |
| A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma E Bachy, S Le Gouill, R Di Blasi, P Sesques, G Manson, G Cartron, ... Nature medicine 28 (10), 2145-2154, 2022 | 276 | 2022 |
| Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study E Bachy, JF Seymour, P Feugier, F Offner, A López-Guillermo, D Belada, ... Journal of Clinical Oncology 37 (31), 2815-2824, 2019 | 266 | 2019 |
| Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious … D Averbuch, G Tridello, J Hoek, M Mikulska, H Akan, ... Clinical Infectious Diseases 65 (11), 1819-1828, 2017 | 265 | 2017 |
| Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts C Sarkozy, MJ Maurer, BK Link, H Ghesquieres, E Nicolas, CA Thompson, ... Journal of Clinical Oncology 37 (2), 144-152, 2019 | 236 | 2019 |
| Early event status informs subsequent outcome in newly diagnosed follicular lymphoma MJ Maurer, E Bachy, H Ghesquières, SM Ansell, GS Nowakowski, ... American journal of hematology 91 (11), 1096-1101, 2016 | 233 | 2016 |
| A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy E Bachy, MJ Maurer, TM Habermann, B Gelas-Dore, D Maucort-Boulch, ... Blood, The Journal of the American Society of Hematology 132 (1), 49-58, 2018 | 209 | 2018 |
| Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations K Rejeski, M Subklewe, M Aljurf, E Bachy, A Balduzzi, P Barba, B Bruno, ... Blood 142 (10), 865-877, 2023 | 154 | 2023 |
| Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, ... Bone marrow transplantation 52 (2), 216-221, 2017 | 149 | 2017 |
| Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA) E Bachy, V Camus, C Thieblemont, D Sibon, RO Casasnovas, L Ysebaert, ... Journal of Clinical Oncology 40 (3), 242-251, 2022 | 148 | 2022 |
| Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival MT Rubio, L Moreira-Teixeira, E Bachy, M Bouillié, P Milpied, T Coman, ... Blood, The Journal of the American Society of Hematology 120 (10), 2144-2154, 2012 | 140 | 2012 |
| Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers G Fossard, F Broussais, I Coelho, S Bailly, E Nicolas-Virelizier, ... Annals of Oncology 29 (3), 715-723, 2018 | 139 | 2018 |
| Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center P Sesques, E Ferrant, V Safar, F Wallet, J Tordo, A Dhomps, L Karlin, ... American journal of hematology 95 (11), 1324-1333, 2020 | 132 | 2020 |
| ABVD (8 cycles) versus BEACOPP (4 escalated cycles≥ 4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial N Mounier, P Brice, S Bologna, J Briere, I Gaillard, M Heczko, J Gabarre, ... Annals of oncology 25 (8), 1622-1628, 2014 | 130 | 2014 |
| Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia PB Staber, M Herling, M Bellido, ED Jacobsen, MS Davids, TM Kadia, ... Blood, The Journal of the American Society of Hematology 134 (14), 1132-1143, 2019 | 127 | 2019 |
| Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised … J Dupuis, F Morschhauser, H Ghesquières, H Tilly, O Casasnovas, ... The Lancet Haematology 2 (4), e160-e165, 2015 | 124 | 2015 |
